Christopher Lieu, MD
Medical Oncology
Locations
Practice Locations
University of Colorado Cancer Center - Anschutz Medical Campus
720-848-0300
UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
720-848-0000
UCHealth Pancreas and Biliary Multidisciplinary Clinic - Anschutz Medical Campus
1-855-824-7262
UCHealth University of Colorado Hospital (UCH)
720-848-0000
Provider Expertise
Clinical Interest for Patients
I am interested in Gastrointestinal Cancers (Colorectal, Pancreatic, Gastric, Esophageal, Hepatocellular, Gallbladder, Bile Duct, Anal, Carcinoma of Unknown (Primary), Drug Development (Experimental Therapeutics) and Translational Research.
Care Philosophy
We strive to provide patient-focused, personalized, multi-disciplinary care for gastrointestinal (GI) cancers. Our specialized providers in Medical Oncology (chemotherapy and targeted therapies), Surgical Oncology, Radiation Oncology, Pathology, Molecular Pathology, Radiology, Interventional Radiology, Nuclear Medicine, Gastroenterology (both Hepatology and Interventional Endoscopy), Nutrition, and Integrative Medicine work together to achieve the best outcomes for our patients. We have cancer-specific multidisciplinary clinics in pancreas, colorectal, gastroesophageal, liver, and neuroendocrine cancers where patients can meet all of their specialty providers in a single clinic visit. Dr. Lieu joined the University of Colorado School of Medicine faculty in 2011. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. Dr. Lieu completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010. Dr. Lieu currently serves as the co-Director of GI Medical Oncology at the University of Colorado Cancer Center, the Vice-Chair of the National Cancer Institute Colon Cancer Task Force, the FDA Oncologic Drugs Advisory Committee (ODAC), and the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.
Specialties
- Internal Medicine ( 2007 )
- Medical Oncology ( 2011 )
Conditions & Treatments
-
Cancers
Biliary Cancer, Cancer Medicine, Cancer Prevention, Colorectal Cancer, Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver), Pancreatic Cancer
-
Digestive System
Gastroenterology (Stomach, Bowel, General GI Problems)
Education & Training
Medical Schools
MD, Wake Forest University School of Medicine (2004)
Undergraduate Schools
BS, University of North Carolina–Chapel Hill (NC) (2000)
Internships
University of Colorado (University Hospital) Program (2005)
Residency Program
University of Colorado (University Hospital) Program (2008)
Fellowships
University of Texas M D Anderson Cancer Center Program (2011)
Professional Memberships
American Association for Cancer Research, Member
American Society of Clinical Oncology, Member
Arnold P. Gold Foundation, Member
Rocky Mountain Oncology Society, Member
Southwest Oncology Group, Member
Research & Grants
Grants
K23CA190949A (2015)
R01CA229259 (2018)
Research Interests for Patients
I am a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. I am interested in resistance mechanisms to targeted therapy in GI cancers, and I was awarded the Conquer Cancer Foundation Career Development Award, NIH K23 grant, and a NIH R01 grant to study targeted therapies in colorectal cancer. I am also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.
information for referring providers
Referral Contact Phone
(720) 848-0300
Referral Contact Fax
720-848-0360
Clinical Interests for Referring Providers
Immunotherapy and targeted therapy clinical trials for patients with colorectal cancer.
Research Interest for Referring Providers
Targeted and immunotherapies for colorectal and GI malignancies, Young-onset colorectal cancer, RAS and BRAF mutated colorectal cancer, Targeted and immunotherapies for pancreatic cancers, Targeted therapies for neuroendocrine cancers